Pfizer Inc. (ETR:PFE)
Market Cap | 117.38B |
Revenue (ttm) | 57.67B |
Net Income (ttm) | 7.28B |
Shares Out | n/a |
EPS (ttm) | 1.28 |
PE Ratio | 16.13 |
Forward PE | 8.48 |
Dividend | 1.57 (7.55%) |
Ex-Dividend Date | May 9, 2025 |
Volume | 28,683 |
Average Volume | 49,245 |
Open | 20.77 |
Previous Close | 20.79 |
Day's Range | 20.70 - 20.82 |
52-Week Range | 18.57 - 29.50 |
Beta | 0.49 |
RSI | 48.01 |
Earnings Date | Aug 5, 2025 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial numbers in USD Financial StatementsNews
Pfizer hemophilia therapy succeeds in late-stage trial

Pfizer's bleeding disorder therapy meets main goal in patients with certain antibodies
Pfizer said on Thursday its hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies.

Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI in Hemophilia A or B with Inhibitors
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI (marstacimab) for adults and adolescents living with hemophilia A or B w...

Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and adolescents liv...

Heads up: Far-right lawmakers look to table no confidence vote against EU's von der Leyen
For some context, Pfizergate refers to the supposed scandal involving EU president von der Leyen and Pfizer itself over the procurement of Covid-19 vaccines in 2021. It is mainly about the lack of tra...

Ursula von der Leyen faces no-confidence vote over Pfizergate
Far-right motion relating to pandemic scandal threatens to derail European Commission president’s second-term agenda
Pfizer Could Be The Turnaround Story In The Pharmaceutical Space
Pfizer declares $0.43 dividend

Pfizer Declares Third-Quarter 2025 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the company’s common stock, payable September 2, 2025, to holders of the Common Stoc...

Pfizer Declares Third-Quarter 2025 Dividend
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the company's common stock, payable September 2, 2025, to...
Don't Sleep On Pfizer: The Turnaround Is Just Getting Started

17 Ideal 'Safer' Dividend Dogs To Buy Out Of 72 June Graham Value All-Stars
I use YCharts' Value Score and Ben Graham Formula Value All Stars, or GASV, to identify large-cap stocks offering strong value and dividend safety. Seventeen out of twenty-four "safer" lowest-priced D...

Top stock price forecast: Plug Power, Uber, and Pfizer
The US stock market bounced back on Tuesday after the truce between Iran and Israel. The Dow Jones, Nasdaq 100, and S&P 500 indices jumped by over 1%, and the bullish momentum continued in the futures...

Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, August 5, 2025. The purpose...

Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, ...

10 'Safer' Dividend Buys Of Barron's Better Bets Than T-Bills For June
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge div...

Bargain Alert: I'm Buying Monthly Dividends Up To 7% Yield
Timing of income is an important consideration. Monthly dividend stocks provide recurring income and faster compounding of wealth. I highlight two monthly dividend payers that are undervalued while su...
Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz
Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.

Ireland sees thousands of jobs at risk from U.S. pharma tariffs
Ireland is running a strong fiscal surplus, driven by corporate taxes from U.S. multinationals like Apple and Pfizer. However, global slowdown and tariff uncertainty put much of that revenue at risk.

Donald Trump Jr. Joins Mark Cuban In Slamming Elizabeth Warren on Healthcare Pricing
Donald Trump Jr . has joined billionaire entrepreneur Mark Cuban in publicly voicing disapproval of Sen. Elizabeth Warren (D-Mass.)’s approach to healthcare pricing. Despite their political difference...

The Dark Side Of Dividend Growth Investing
Dividend growth investing is a powerful way to compound wealth and set yourself up for financial independence. However, it also has some real drawbacks. I share 3 aspects of the dark side of dividend ...

I'm Buying Dividend Giants At Huge Discounts
Now is a great time to be an income and value investor, particularly in the energy and pharmaceutical spaces. I highlight 2 undervalued names that provide well-covered dividends with a strong growth o...
Will Pfizer Slash Its >7% Yielding Dividend? I Wouldn't Rule It Out

Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
A heated debate over the U.S. healthcare system erupted on X, pitting billionaire entrepreneur Mark Cuban against Sen. Elizabeth Warren (D-Mass) over the root causes of soaring drug prices. What Happe...